Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Casirivimab/imdevimab  COVID-19 treatment studies for Casirivimab/i..  C19 studies: Casirivimab/i..  Casirivimab/i..   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
 
    
  
Casirivimab/imdevimab for COVID-19
27 studies from 402 scientists
58,886 patients in 6 countries
Statistically significant improvement for mortality, hospitalization, progression, recovery, cases, and viral clearance.
47%, 33% improvement for early and late treatment CI [29-60%], [-17-61%]
Efficacy variant dependent. In Vitro research suggests a lack of efficacy for omicron. ADE shown In Vitro.
COVID-19 Casirivimab/imdevimab studies. Jun 2023. c19early.org/r
0 0.5 1 1.5+ All studies 52% With exclusions 53% Mortality 40% Hospitalization 42% Recovery 33% Cases 80% Viral clearance 55% RCTs 61% RCT mortality 20% Prophylaxis 93% Early 47% Late 33% Favorscasirivimab/im.. Favorscontrol
Casirivimab/imdevimab COVID-19 studies. Efficacy is variant dependent. In Vitro studies suggest a lack of efficacy for omicron [Liu, Sheward, Tatham, VanBlargan]. Monoclonal antibody use with variants can be associated with prolonged viral loads, clinical deterioration, and immune escape [Choudhary]. ADE shown In Vitro [Shimizu]. Recent:
Kip.
Casirivimab/imdevimab has been officially adopted in 42 countries. Submit updates/corrections.
Jun 3
Covid Analysis (Preprint) (meta analysis) Casirivimab/imdevimab for COVID-19: real-time meta analysis of 27 studies
Statistically significant improvements are seen for mortality, hospitalization, progression, recovery, cases, and viral clearance. 20 studies from 14 independent teams in 4 different countries show statistically significant improvements..
Apr 4
Kip et al., Annals of Internal Medicine, doi:10.7326/M22-1286 Evolving Real-World Effectiveness of Monoclonal Antibodies for Treatment of COVID-19
46% lower combined mortality/hospitalization [p<0.0001]. Retrospective 2,571 patients treated with mAbs in the USA, and 5,135 control patients, showing lower combined mortality/hospitalization for bamlanivimab, bamlanivimab/etesevimab, casirivimab/imdevimab, sotrovimab, and bebtelovimab, with s..
Dec 19
Hussein et al., BMJ Open, doi:10.1136/bmjopen-2022-064953 Real-world effectiveness of casirivimab and imdevimab among patients diagnosed with COVID-19 in the ambulatory setting: a retrospective cohort study using a large claims database
60% lower combined mortality/hospitalization [p<0.0001]. Retrospective 73,759 outpatients treated with casirivimab/imdevimab, showing lower mortality with treatment. This result is subject to potentially substantial confounding by indication - patients with more severe cases may be more likely ..
Dec 2
Gershengorn et al., PLOS ONE, doi:10.1371/journal.pone.0278770 The clinical effectiveness of REGEN-COV in SARS-CoV-2 infection with Omicron versus Delta variants
95% higher hospitalization [p=0.09]. Retrospective 2,083 outpatients in the USA, showing higher risk of hospitalization with casirivimab/imdevimab, without statistical significance. There may be significant unadjusted confounding by indication.
Nov 17
Planas et al., bioRxiv, doi:10.1101/2022.11.17.516888 (Preprint) (In Vitro) Resistance of Omicron subvariants BA.2.75.2, BA.4.6 and BQ.1.1 to neutralizing antibodies
In Vitro study suggesting a lack of efficacy for casirivimab/imdevimab with BA.2.75.2 and BQ.1.1.
Oct 15
Nagler et al., American Journal of Health-System Pharmacy, doi:10.1093/ajhp/zxac295 The impact of COVID-19 monoclonal antibodies on clinical outcomes: A retrospective cohort study
61% higher mortality [p=0.4], 51% higher ICU admission [p=0.5], 49% lower hospitalization [p<0.0001], and 39% lower progression [p<0.0001]. PSM retrospective 1,344 patients in the USA, showing lower hospitalization with monoclonal antibody treatment. Authors combine patients treated with bamlanivimab, bamlanivimab/etesevimab, or casirivimab/imdevimab.
Sep 16
Shimizu et al., Scientific Reports, doi:10.1038/s41598-022-19993-w Reevaluation of antibody-dependent enhancement of infection in anti-SARS-CoV-2 therapeutic antibodies and mRNA-vaccine antisera using FcR- and ACE2-positive cells
In Vitro study showing that casirivimab/imdevimab may induce antibody-dependent enhancement (ADE) within a specific concentration range. No ADE was observed for sotrovimab.
Sep 12
Williams et al., American Journal of Obstetrics and Gynecology, doi:10.1016/j.ajog.2022.09.017 Effectiveness of REGEN-COV combination monoclonal antibody infusion to reduce risk of COVID-19 hospitalization in pregnancy: A retrospective cohort study
21% higher need for oxygen therapy [p=0.87], 1% higher severe cases [p=0.99], and 14% lower hospitalization [p=0.9]. Retrospective 764 pregnant patients with COVID-19 in the USA, 88 treated with casirivimab/imdevimab, showing no significant difference in outcomes.
Sep 9
Kneidinger et al., Infection, doi:10.1007/s15010-022-01914-8 Outcome of lung transplant recipients infected with SARS-CoV-2/Omicron/B.1.1.529: a Nationwide German study
97% lower severe cases [p=0.45]. Retrospective 218 COVID+ lung transplant patients in Germany, showing no significant difference in severe cases with early casirivimab/imdevimab use.
Jul 11
Kadowaki et al., Journal of Infection and Chemotherapy, doi:10.1016/j.jiac.2022.07.002 Timing of REGEN-COV administration and progression to severe COVID-19
Retrospective 342 patients in Japan, showing significantly greater efficacy of casirivimab/imdevimab with earlier treatment. The proportion of patients progressing to severe COVID-19 increased daily from symptom onset and increased sharpl..
Jun 4
Levey et al., American Journal of Obstetrics & Gynecology MFM, doi:10.1016/j.ajogmf.2022.100673 Outcomes of pregnant patients treated with REGEN-COV during the COVID-19 pandemic
108% higher hospitalization [p=0.15]. Retrospective 86 pregnant COVID-19 patients, 36 treated with casirivimab/imdevimab, showing no significant difference in COVID-19 outcomes with treatment.
May 26
Miyashita et al., Journal of Infection and Chemotherapy, doi:10.1016/j.jiac.2022.05.012 Clinical efficacy of casirivimab-imdevimab antibody combination treatment in patients with COVID-19 Delta variant
46% lower need for oxygen therapy [p=0.004]. Retrospective 461 patients treated with casirivimab/imdevimab in Japan, and 461 matched controls, showing lower oxygen requirements with treatment.
May 5
Faraone et al., Research Square, doi:10.21203/rs.3.rs-1170976/v1 (Preprint) REGEN-COV antibody cocktail (casirivimab/imdevimab) for the treatment of inpatients with early hospital-acquired COVID-19: a single center experience
92% lower mortality [p=0.03] and 94% lower need for oxygen therapy [p=0.02]. Retrospective 34 patients with hospital-acquired COVID-19, showing lower mortality and oxygen requirements with early casirivimab/imdevimab treatment.
Mar 31
Wilden et al., Journal of the National Comprehensive Cancer Network, doi:10.6004/jnccn.2021.7309 Real World Outcomes of Cancer Patients With SARS-CoV-2 Infection Receiving Monoclonal Antibodies
82% lower hospitalization [p=0.004]. Retrospective 395 patients in the USA receiving casirivimab/imdevimab or bamlanivimab, showing lower risk of hospitalization with treatment, statistically significant for casirivimab/imdevimab.
Feb 28
Wei et al., medRxiv, doi:10.1101/2022.02.28.22270796 (Preprint) Real-world Effectiveness of Casirivimab and Imdevimab in Patients With COVID-19 in the Ambulatory Setting: An Analysis of Two Large US National Claims Databases
61% lower combined mortality/hospitalization [p<0.0001] and 61% lower hospitalization [p<0.0001]. Retrospective 4,396 casirivimab/imdevimab patients in the USA, showing lower combined mortality/hospitalization (CDM database) and lower hospitalization (PMTX+ database) with treatment.
Feb 16
Zhou et al., bioRxiv, doi:10.1101/2022.02.15.480166 (Preprint) (In Vitro) SARS-CoV-2 Omicron BA.2 Variant Evades Neutralization by Therapeutic Monoclonal Antibodies
In Vitro study showing that omicron BA.2 evades all monoclonal antibodies tested, including sotrovimab and tixagevimab/cilgavimab which retained activity for omicron BA.1.
Feb 3
Osugi et al., Cureus, doi:10.7759/cureus.21882 Clinical Prognosis of Patients With Mild COVID-19 Treated With Casirivimab/Imdevimab in Japan
24% lower hospitalization [p=0.65]. Retrospective 104 outpatients in Japan, 30 treated with casirivimab/imdevimab, showing no significant difference in hospitalization.
Jan 31
Shopen et al., medRxiv, doi:10.1101/2022.01.29.22270090 (Preprint) Doubtful Clinical Benefit of Casirivimab-Imdevimab Treatment for Disease Severity Outcome of High-Risk Patients with SARS-CoV-2 Delta Variant Infection
46% higher severe cases [p=0.26]. Retrospective 359 COVID+ patients in Israel, 116 treated with casirivimab/imdevimab, showing no significant difference with treatment in multivariable analysis.
Jan 24
Tatham et al., bioRxiv, doi:10.1101/2022.01.23.477397 (Preprint) Lack of Ronapreve (REGN-CoV; casirivimab and imdevimab) virological efficacy against the SARS-CoV 2 Omicron variant (B.1.1.529) in K18-hACE2 mice
K18-hACE2 mouse study showing that casirivimab/imdevimab was not effective for omicron at doses 2x higher than those effective for previous variants.
Jan 14
O'Brien et al., JAMA, doi:10.1001/jama.2021.24939768 Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial
85% lower hospitalization [p=0.25], 92% fewer combined hospitalization/ER visits [p=0.03], 33% fewer symptomatic cases [p=0.04], and 40% improved viral clearance [p=0.001]. RCT 204 asymptomatic COVID+ patients, 100 treated with subcutaneous casirivimab/imdevimab, showing lower development of symptoms, lower hospitalization, and faster viral clearance with treatment. Study conducted prior to widespread circul..
Dec 21
2021
Suzuki et al., medRxiv, doi:10.1101/2021.12.19.21268078 (Preprint) Real-world clinical outcomes of treatment with casirivimab-imdevimab among patients with mild-to-moderate coronavirus disease 2019 during the Delta variant pandemic
45% lower progression [p=0.02]. Retrospective 949 patients in Japan, 314 treated with casirivimab/imdevimab showing significantly lower risk of deterioration with treatment.
Dec 20
2021
Sheward et al., bioRxiv, doi:10.1101/2021.12.19.473354 (Preprint) (In Vitro) Variable loss of antibody potency against SARS-CoV-2 B.1.1.529 (Omicron)
In Vitro study showing that omicron is substantially resistant to neutralization by monoclonal antibodies REGN10933, REGN10987, Ly-CoV016 and Ly-CoV555. S309 (the parent of Sotrovimab) had only 2-fold loss in potency.
Dec 19
2021
Komagamine et al., Journal of General and Family Medicine, doi:10.1002/jgf2.516 The effect of casirivimab with imdevimab on disease progression in nonsevere COVID-19 patients in a single hospital in Japan
92% lower ICU admission [p=0.04], 68% lower progression [p=0.006], and 29% shorter hospitalization [p=0.001]. Combined retrospective/prospective study in Japan with 53 casirivimab/imdevimab patients and 75 control patients, showing significantly lower progression with treatment.
Dec 17
2021
VanBlargan et al., bioRxiv, doi:10.1101/2021.12.15.472828 (Preprint) (In Vitro) An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by several therapeutic monoclonal antibodies
In vitro study (Vero-TMPRSS2 and Vero-hACE2-TMPRSS2) showing complete loss of inhibitory activity for B.1.1.529 omicron with LY-CoV555, LY-CoV016, REGN10933, REGN10987, and CT-P59, ~12-fold decrease for COV2-2196/COV2-2130, and minimal ch..
Dec 15
2021
Liu et al., bioRxiv, doi:10.1101/2021.12.14.472719 (Preprint) (In Vitro) Striking Antibody Evasion Manifested by the Omicron Variant of SARS-CoV-2
In Vitro study (Vero-E6-TMPRSS2) showing 18 of 19 monoclonal antibodies were no longer effective or significantly impaired with B.1.1.529 omicron.
Dec 1
2021
McCreary et al., medRxiv, doi:10.1101/2021.11.30.21266756 (Preprint) Association of subcutaneous or intravenous route of administration of casirivimab and imdevimab monoclonal antibodies with clinical outcomes in COVID-19
93% lower mortality [p=0.009], 56% lower combined mortality/hospitalization [p=0.0003], 48% lower hospitalization [p=0.005], and 40% fewer combined hospitalization/ER visits [p=0.003]. Prospective study comparing subcutaneous and intravenous casirivimab/imdevimab, and comparing to a PSM matched control set, showing significantly lower mortality and hospitalization with treatment. Controls were matched with EUA-eligible ..
Nov 16
2021
Isa et al., medRxiv, doi:10.1101/2021.11.10.21265889 (Preprint) Repeat Subcutaneous Administration of REGEN-COV® in Adults is Well-Tolerated and Prevents the Occurrence of COVID-19
93% fewer symptomatic cases [p=0.002] and 93% fewer cases [p=0.002]. RCT 969 patients, 729 treated with monthly subcutaneous casirivimab/imdevimab, showing significantly lower risk of COVID-19 with treatment. There were no grade 3 injection site reactions or hypersensitivity reactions. Slightly more TEAEs ..
Nov 8
2021
Somersan-Karakaya et al., The Journal of Infectious Diseases, doi:10.1093/infdis/jiac320 (date from earlier preprint) Casirivimab and Imdevimab for the Treatment of Hospitalized Patients With COVID-19
36% lower mortality [p=0.02], 31% lower combined mortality/intubation [p=0.03], and 30% higher hospital discharge [p=0.02]. RCT 1,336 hospitalized patients with symptom onset <=10 days on low-flow or no supplemental oxygen, showing lower mortality with treatment. Cohorts 2&3 were paused mid-trial due to increased deaths in the treatment arm and these results w..
Nov 8
2021
Regeneron Press Release (News) New phase 3 analyses show that a single dose of REGEN-COV® (casirivimab and imdevimab) provides long-term protection against COVID-19
92% lower hospitalization [p=0.03], 81% fewer cases [p<0.0001], 89% fewer combined hospitalization/ER visits [p=0.06], and 81% fewer symptomatic cases [p<0.0001]. Long-term results for PEP RCT NCT04452318, with 841 baseline seronegative casirivimab/imdevimab patients and 842 placebo patients, showing significantly lower cases with treatment.
Nov 4
2021
Kakinoki et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2022.01.067 (date from earlier preprint) Impact of Antibody Cocktail Therapy Combined with Casirivimab and Imdevimab on Clinical Outcome for Covid-19 patients in A Real-Life Setting: A Single Institute Analysis
58% lower progression [p=0.05]. Retrospective 55 patients in Japan treated a median of 3 days from symptom onset with casirivimab/imdevimab, and 53 control patients, showing lower risk of further treatment including oxygen or antivirals.
Nov 2
2021
Kaleta et al., Research Square, doi:10.21203/rs.3.rs-995033/v1 (Preprint) (In Vitro) Antibody escape and global spread of SARS-CoV-2 lineage A.27
Anaysis of antibody escape showing variant A.27 completely escaped neutralization with LY-COV555 and partially with REGN10987. B.1.617.2 escaped these antibodies in a similar manner, suggesting that L452R facilitates the escape. Authors n..
Oct 31
2021
Razonable et al., EClinicalMedicine, doi:10.1016/j.eclinm.2021.101102 Casirivimab–Imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate coronavirus disease-19
75% lower mortality [p=0.37], 29% lower ICU admission [p=0.77], and 67% lower hospitalization [p=0.001]. Retrospective 696 patients treated with casirivimab/imdevimab, and 696 matched controls, showing lower hospitalization with treatment. Authors only included patients with documented followup, which is likely to disproportionately bias the..
Oct 20
2021
Bierle et al., The Journal of Infectious Diseases, doi:10.1093/infdis/jiab570 (date from earlier preprint) Monoclonal Antibody Treatment of Breakthrough COVID-19 in Fully Vaccinated Individuals with High-Risk Comorbidities
89% lower ICU admission [p=0.16], 85% lower need for oxygen therapy [p<0.0001], and 75% lower hospitalization [p<0.0001]. Retrospective 1,395 vaccinated COVID-19 cases, showing significantly lower hospitalization and oxygen supplementation with monoclonal antibody treatment, primarily casirivimab-imdevimab. Hospitalization was significantly associated with..
Oct 8
2021
Cooper et al., Open Forum Infectious Diseases, doi:10.1093/ofid/ofab512 Real-world Assessment of 2,879 COVID-19 Patients Treated with Monoclonal Antibody Therapy: A Propensity Score-Matched Cohort Study
77% lower mortality [p=0.18], 48% lower ICU admission [p=0.14], and 52% lower hospitalization [p<0.0001]. Retrospective 2,879 patients and matched controls in the USA, showing significantly lower mortality and hospitalization with bamlanivimab, bamlanivimab/etesevimab, and casirivimab/imdevimab. There was significantly lower hospitalization w..
Jun 23
2021
Webb et al., Open Forum Infectious Diseases, doi:10.1093/ofid/ofab331 Real-World Effectiveness and Tolerability of Monoclonal Antibody Therapy for Ambulatory Patients with Early COVID-19
91% lower hospitalization [p=0.0003]. Retrospective 115 patients treated with casirivimab/imdevimab showing lower mortality, hospital admission, and emergency department visits with treatment. Authors incorrectly state that "no other COVID-19 therapies for ambulatory pat..
Jun 16
2021
Horby et al., The Lancet, doi:10.1016/S0140-6736(22)00163-5 (date from earlier preprint) Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
6% lower mortality [p=0.16] and 1% higher ventilation [p=0.88]. RCT 9,785 hospitalized patients in the UK showing lower mortality with casirivimab/imdevimab, with statistical significance reached for baseline seronegative patients.
May 21
2021
Weinreich et al., NEJM, doi:10.1056/NEJMoa2108163 (date from earlier preprint) REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19
71% lower combined mortality/hospitalization [p=0.001] and 29% faster recovery [p=0.001]. RCT 4,057 outpatients with >=1 risk factor for severe disease, showing significantly lower combined hospitalization/death, and significantly faster recovery with treatment. Median time from onset of symptoms 3 days. NCT04425629.
Apr 12
2021
O'Brien et al., NEJM, doi:10.1056/NEJMoa2109682 (press release 4/12/21) Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19
89% fewer combined hospitalization/ER visits [p=0.06], 81% fewer symptomatic cases [p<0.0001], 62% faster recovery [p=0.0001], and 69% faster viral clearance [p=0.0001]. Prophylaxis trial reporting lower hospitalization/ER and symptomatic cases, and faster recovery with 1,200mg subcutaneous casirivimab with imdevimab. The same trial has updated results available in [c19regn.com]. NCT04452318.
Mar 23
2021
Regeneron Press Release (Preprint) New phase III data shows investigational antibody cocktail casirivimab and imdevimab reduced hospitalisation or death by 70% in non-hospitalised patients with COVID-19
71% lower combined mortality/hospitalization [p<0.0001] and 29% faster recovery [p=0.0001]. Press release for new phase III data showing lower hospitalization/mortality, and faster symptom resolution among the subset of patients with at least one risk factor. Some variants may escape antibodies [cell.com].
Jan 26
2021
Regeneron Press Release (Preprint) Regeneron Reports Positive Interim Data with REGEN-COV™ Antibody Cocktail used as Passive Vaccine to Prevent COVID-19
94% fewer symptomatic cases [p=0.009] and 48% fewer cases [p=0.07]. Interim results of REGEN-COV prophylaxis showing 100% prevention of symptomatic infection (8/223 placebo vs. 0/186 REGEN-COV), and approximately 50% lower overall rates of infection (symptomatic and asymptomatic) (23/223 placebo vs. 10/18..
Sep 29
2020
Regeneron Press Release (Preprint) Regeneron's REGN-COV2 antibody cocktail reduced viral levels and improved symptoms in non-hospitalized COVID-19 patients
38% faster recovery [p=0.22]. Analysis of the first 275 patients in a trial of the REGN-COV2 antibody cocktail showing reductions in viral load and the time to alleviate symptoms in non-hospitalized patients with COVID-19. Greatest improvements were seen with patients..
Aug 21
2020
Baum et al., Science, 21 Aug 2020, 369:6506, 1014-1018, doi:10.1126/science.abd0831 (In Vitro) Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies
In Vitro study showing that, under pressure from individual antibodies, mutant viruses were rapidly selected that evaded the blocking function of all individual antibodies tested, including antibodies that potently bind to highly-conserve..
Aug 21
2020
Hansen et al., Science, 21 Aug 2020, 369:6506, 1010-1014, doi:10.1126/science.abd0827 Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail
Study using humanized mice and blood samples from recovered COVID-19 patients to generate antibodies targeting multiple different regions of the critical receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. The spike protein on ..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit